| Original language | English (US) |
|---|---|
| Pages (from-to) | 355-360 |
| Number of pages | 6 |
| Journal | Clinical Lymphoma, Myeloma and Leukemia |
| Volume | 21 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2021 |
Keywords
- Immunotherapy
- Monoclonal antibodies
- Multiple myeloma
- Plasma cell dyscrasias
- Targeted therapy
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. / Parrondo, Ricardo D.; Moustafa, Muhamad Alhaj; Reeder, Craig; Sher, Taimur; Roy, Vivek; Muchtar, Eli; Warsame, Rahma; Alegria, Victoria; Gonsalves, Wilson; Dingli, David; Hayman, Suzanne; Kapoor, Prashant; Chanan-Khan, Asher A.; Ailawadhi, Sikander.
In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, No. 5, 05.2021, p. 355-360.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia
AU - Parrondo, Ricardo D.
AU - Moustafa, Muhamad Alhaj
AU - Reeder, Craig
AU - Sher, Taimur
AU - Roy, Vivek
AU - Muchtar, Eli
AU - Warsame, Rahma
AU - Alegria, Victoria
AU - Gonsalves, Wilson
AU - Dingli, David
AU - Hayman, Suzanne
AU - Kapoor, Prashant
AU - Chanan-Khan, Asher A.
AU - Ailawadhi, Sikander
N1 - Funding Information: M.A.M. performs consultancy for Acrotech. P.K. received honoraria from Celgene and Takeda, preforms consultancy for Cellectar and Sanofi, and receives research funding from Janssen, Sanofi, Amgen, Takeda, and GlaxoSmithKline. D.D. performs consultancy for Apellis, Alexion, Janssen, Sanofi-Genzyme, Millennium, and Rigel and receives research funding rom Bristol Myers Squibb and Karyopharm Therapeutics. S.A. receives honoraria from Celgene and Takeda and research funding from Amgen, Janssen, Pharmacyclics, Cellectar, Bristol-Myers Squibb, Phosphatin, and MedImmune. The other authors have stated that they have no conflict of interest. Funding Information: M.A.M. performs consultancy for Acrotech. P.K. received honoraria from Celgene and Takeda, preforms consultancy for Cellectar and Sanofi, and receives research funding from Janssen , Sanofi , Amgen , Takeda , and GlaxoSmithKline . D.D. performs consultancy for Apellis, Alexion, Janssen, Sanofi-Genzyme, Millennium, and Rigel and receives research funding rom Bristol Myers Squibb and Karyopharm Therapeutics. S.A. receives honoraria from Celgene and Takeda and research funding from Amgen , Janssen , Pharmacyclics , Cellectar , Bristol-Myers Squibb , Phosphatin , and MedImmune . The other authors have stated that they have no conflict of interest.
PY - 2021/5
Y1 - 2021/5
KW - Immunotherapy
KW - Monoclonal antibodies
KW - Multiple myeloma
KW - Plasma cell dyscrasias
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=85100662746&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100662746&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2021.01.002
DO - 10.1016/j.clml.2021.01.002
M3 - Article
C2 - 33563579
AN - SCOPUS:85100662746
VL - 21
SP - 355
EP - 360
JO - Clinical Lymphoma
JF - Clinical Lymphoma
SN - 2152-2669
IS - 5
ER -